Skip to main content

Advertisement

Table 9 Survival in trials comparing gemcitabine to gemcitabine plus other cytotoxic agent

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year Treatment regimen Median survival (mo) P HR 95% CI
Oettle 2005 Gemcitabine 6.3 0.848 0.98 0.82 – 1.18
   Gemcitabine + Pemetrexed 6.2    
Rocha Lima 2004 Gemcitabine 6.6 0.789 1.04 0.84 – 1.30
   Gemcitabine + Irinotecan 6.3    
Stathopoulos 2006 Gemcitabine 6.5 0.970 na na
   Gemcitabine + Irinotecan 6.4    
O'Reilly 2004 Gemcitabine 6.2 0.52 0.93 0.74 – 1.17
   Gemcitabine + Exatecan 6.7    
  1. na = data not available;